There is an urgent need for novel therapeutic strategies for the treatment of nonfunctional pituitary adenomas (NFPAs), especially those that are invasive. The folate receptor (FR)␣ is overexpressed in several cancers, including NFPA. The aim of this study was to determine the efficacy of FR␣-targeted liposomes loaded with doxorubicin (F-L-DOX) in the treatment of NFPA. We evaluated targeting, cytotoxicity, antiinvasive, and proapoptotic activity of F-L-DOX in 25 primary cell lines derived from patients with NFPAs. We found that these liposomes effectively targeted NFPA cells through FR␣ and that endocytosis of the liposomes was blocked by 1mM free folic acid. F-L-DOX inhibited proliferation of NFPA cells and promoted apoptosis through activation of caspase-8, caspase-9, and caspase-3/7 more effectively than L-DOX. Furthermore, F-L-DOX also exerted greater antiinvasive ability in NFPA cells than L-DOX through suppression of the secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9. Addition of 1mM free folic acid significantly reduced the pleotropic effects of F-L-DOX in NFPA cells, suggesting that FR␣ plays a critical role in mediating the antitumor effect of F-L-DOX. Our findings warrant further investigation of F-L-DOX as an alternative therapeutic strategy for the treatment of NFPAs that express FR␣. (Endocrinology 154: 1414 -1423, 2013) 
There is an urgent need for novel therapeutic strategies for the treatment of nonfunctional pituitary adenomas (NFPAs), especially those that are invasive. The folate receptor (FR)␣ is overexpressed in several cancers, including NFPA. The aim of this study was to determine the efficacy of FR␣-targeted liposomes loaded with doxorubicin (F-L-DOX) in the treatment of NFPA. We evaluated targeting, cytotoxicity, antiinvasive, and proapoptotic activity of F-L-DOX in 25 primary cell lines derived from patients with NFPAs. We found that these liposomes effectively targeted NFPA cells through FR␣ and that endocytosis of the liposomes was blocked by 1mM free folic acid. F-L-DOX inhibited proliferation of NFPA cells and promoted apoptosis through activation of caspase-8, caspase-9, and caspase-3/7 more effectively than L-DOX. Furthermore, F-L-DOX also exerted greater antiinvasive ability in NFPA cells than L-DOX through suppression of the secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9. Addition of 1mM free folic acid significantly reduced the pleotropic effects of F-L-DOX in NFPA cells, suggesting that FR␣ plays a critical role in mediating the antitumor effect of F-L-DOX. Our findings warrant further investigation of F-L-DOX as an alternative therapeutic strategy for the treatment of NFPAs that express FR␣. (Endocrinology 154: 1414 -1423, 2013) P ituitary adenomas (PAs) are the second most common intracranial neoplasms, accounting for approximately 10% of primary brain tumors (1), although autopsy studies indicate a higher incidence of 25% (2) . PAs are associated with significant morbidity and mortality due to hormone hypersecretion and mass effects (2) . Nonfunctional PAs (NFPAs) are the most common type, accounting for approximately 30% of PAs (3) . Because of their hormonal inactivity, NFPAs are often difficult to diagnose until they are large enough to cause tumor mass effects, such as hypopituitarism, visual field defects, or headaches. The firstline treatment is surgery. However, total resection may not be possible, because more than 40% of NFPAs are locally invasive and infiltrate the dura, bones, and sinuses (3, 4) , leading to a high recurrence rate with a poor clinical outcome. Although postoperative radiotherapy may be effec-tive in preventing tumor regrowth, it is associated with severe complications and has frequently been withheld by some clinicians in the past decade (5, 6 ). Furthermore, current chemotherapeutic regimens for the treatment of NFPAs are mainly based on dopamine agonists and somatostatin analogs, which have clinical limitations (7, 8) . As a result, there is an urgent need to determine new therapeutic biomarkers and develop novel antitumor agents against these refractory nonfunctional adenomas.
Recent research into folate receptors (FRs) has provided new perspectives on targeted imaging, diagnosis, and therapy of NFPAs. Membrane FRs, including FR␣ and FR␤, are glycosylphosphatidylinositol-anchored glycoproteins that recognize and internalize folate via endocytosis. FR␣ expression is amplified in over 90% of ovarian carcinomas and at varying frequencies in other epithelial cancers (9) . FR␤ is expressed in a nonfunctional form in neutrophils, and in a functional form in activated macrophages and myeloid leukemias (10) . In contrast, most normal tissues do not express either FR isoform (11) . Folic acid (folate) is a high-affinity ligand for FR and retains high binding affinity after derivatization via one of its carboxyl groups. Because of its small size and bioavailability, folate has become one of the most widely investigated targeting ligands for tumor-specific drug delivery (12) (13) (14) . Because targeted delivery via selective cellular markers can potentially increase the efficacy and reduce the toxicity of therapeutic agents, a variety of molecules and drug carriers, including chemotherapeutic agents, imaging agents, oligonucleotides, proteins, haptens, gene transfer vectors, nanoparticles, and liposomes, have been conjugated to folate and evaluated with respect to FR␣-targeted diagnosis and therapy (15) . These FR␣-targeted agents have shown promising efficacy in preclinical models and have significant potential for future clinical application in a wide range of cancers, including ovarian carcinomas and nonsmall cell lung cancer (15) .
Previous studies have demonstrated that FR␣ is overexpressed in NFPAs but not in FPAs and normal pituitary glands (16, 17) . Moreover, our latest study showed that expression of FR␣ in NFPAs was positively correlated with tumor invasiveness and proliferation (18) . In a recent study (19) , we reported that a novel lipophilic folate derivative, FR␣-targeted liposomal doxorubicin (F-L-DOX), is specifically taken up by FR␣-overexpressing KB cells, which are derived from the human cervical cancer HeLa cell line, and showed greater cytotoxicity than nontargeted liposomal DOX (L-DOX). Because of the unique FR␣ expression profile in NFPAs, FR␣ may be useful for NFPA-targeted imaging and therapy.
In the present study, we assessed the targeting and cytotoxic efficacy of FR␣-targeted liposomal doxorubicin (F-L-DOX) in 25 human primary PA cell lines. We further evaluated the mechanisms involved in the antitumor effect of F-L-DOX in NFPAs.
Materials and Methods

Materials
FR␣-targeted liposomal calcein (F-L-calcein), nontargeted liposomal calcein (L-calcein), L-DOX, and F-L-DOX were synthesized as described previously (19) . Free folate, DOX, calcein, and Accutase were obtained from Sigma-Aldrich (Shanghai, People's Republic of China). Folate-free RPMI 1640 medium was purchased from Invitrogen (Beijing, People's Republic of China). The cell counting kit (CCK)-8 was obtained from Dojindo Laboratories (Kumamoto, Japan), and the cell death detection ELISA plus kit was purchased from Roche (Mannheim, Germany). The DeadEnd Fluorometric terminal deoxynucleotidyl transferase 2Ј-deoxyuridine, 5Ј-triphosphate nick end labeling (TUNEL) system and the Caspase-Glo 3/7, Caspase-Glo 8, and Caspase-Glo 9 assay systems were supplied by Promega (Beijing, People's Republic of China). Primary antibodies for cleaved caspase-8, cleaved caspase-3, and cleaved caspase-9 and B-cell CLL/lymphoma 2 (Bcl-2) and poly(ADP-ribose) polymerase (PARP) (intact and cleaved fragments) were obtained from Cell Signaling Technology (Danvers, Massachusetts). The primary antibody for Bcl-2-associated X protein (Bax) was purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, California) and the mouse anti-FR␣ antibody (LS-C23683) from Lifespan BioSciences (Seattle, Washington). The cyanine 3 affinipure goat antimouse IgG secondary antibody (E031610-01) was purchased from EarthOx (San Francisco, California). College and all patients provided informed consent for the clinical investigation and the in vitro study. These specimens included newly diagnosed NFPAs (n ϭ 34, 24 silent gonadotroph cell adenomas and 10 null cell adenomas), prolactin (PRL) PAs (n ϭ 3), GH PAs (n ϭ 3), and ACTH PAs (n ϭ 3). To generate primary cell cultures, tumor samples were minced and digested in Accutase (Invitrogen) containing 1-mg deoxyribonuclease (Sigma, Beijing, People's Republic of China) at 37°C for 1 hour. After digestion, cell suspensions were passed through a 40-m cell strainer (Becton Dickinson, Shanghai, People's Republic of China), washed twice in PBS, and cultured in folate-free RPMI 1640 media (Invitrogen) supplemented with 10% fetal bovine serum (FBS), B-27 Supplement, N-2 Supplement (Gibco, Beijing, People's Republic of China), penicillin (100 U/mL; Gibco), streptomycin (100 g/mL; Gibco), epidermal growth factor (20 ng/mL; Peprotech, Suzhou, People's Republic of China), and basic fibroblast growth factor (20 ng/mL; Peprotech).
Primary cell culture
Confocal immunofluorescence staining of FR␣
FR␣ expression on the membrane of primary PA cells was analyzed by fluorescence immunocytochemistry. Forty-three primary PA cell lines and HeLa cells (as a positive control) were cultured on glass-bottomed dishes (Nest Biotechnology Corp, Shanghai, People's Republic of China) coated with 10-L BD Matrigel Basement Membrane Matrix at a density of 5 ϫ 10 3 cells/well in folate-free RPMI 1640. Two days later, the cells were fixed with 4% paraformaldehyde in 0.1M PBS (pH 7.4; 30 min), washed twice with PBS, and permeabilized for 5 minutes with 0.5% Triton X-100. Subsequently, the cells were incubated with blocking medium (PBS containing 10% normal horse serum and 2% BSA) to saturate nonspecific IgG binding sites and then incubated overnight at 4°C with primary antibody specific for FR␣ (LS-C23683; Lifespan BioSciences). The cells were washed with PBS 3 times and incubated with cyanine 3 affinipure goat antimouse IgG (E031610-01; EarthOx) for 2 hours at room temperature. Cells were finally washed with PBS and coverslipped with fluorescence mounting medium before visualization under a confocal laser microscope (Zeiss 510; Zeiss, Heidelberg, Germany). Image analysis was performed using the standard system operating software provided with the Zeiss 510 microscope (version 2.01).
Uptake of FR␣-targeted liposomes by PA cells
Primary cell lines derived from 25 cases of PA (20 cases of NFPA, including 14 that overexpressed FR␣, 1 case of ACTH, 2 cases of GH, and 2 cases of PRL), 13 males and 12 females, were grown in a cell sphere, resuspended by brief treatment with Accutase, and washed 3 times with folate-free RPMI 1640. Cells were cultured on 6-well plates coated with 100-L Matrigel Basement Membrane Matrix (Becton Dickinson) in folate-free RPMI 1640 supplemented with penicillin and streptomycin for 48 hours before the uptake test. L-calcein or F-L-calcein was added to each well, and plates were incubated for 1 hour at 37°C. To determine the role of FR␣ binding, 1mM free folate was added to the incubation media in some samples of the FR␣-targeted group. After incubation, cells were washed 3 times with cold PBS to remove unbound calcein and examined on a Nikon Eclipse 800 fluorescence microscope (Nikon, Melville, New York). To quantify uptake, cells were lysed in 0.5-mL PBS containing 1% Triton X-100, and the fluorescence intensity of the cellular lysate was measured at 495-nm excitation and 520-nm emission in a Spectra Max Gemini microplate reader (Molecular Devices, Sunnyvale, California).
Cell proliferation/viability
The inhibitory effect of the drugs on cell proliferation was determined using the CCK-8 assay as described previously (20) . Primary cultures from 20 cases of NFPA, 1 case of ACTH cells, 2 cases of GH, and 2 cases of PRL were plated in 96-well plates coated with 10-L BD Matrigel Basement Membrane Matrix at 5 ϫ 10 3 cells/well. After incubation for 24 hours, free DOX (1M, 5M, 10M, or 20M), L-DOX (1M, 5M, 10M, or 20M), or F-L-DOX (1M, 5M, 10M, or 20M) was added to the respective wells with or without 1mM free folate. After incubation at 37°C for 2 hours, the cells were washed twice and cultured in fresh folate-free RPMI 1640 for an additional 48 hours. Cell viability was evaluated by the CCK-8 assay. Briefly, 10-L CCK-8 was added to each well followed by incubation at 37°C for 3 hours. Absorbance was measured at a wavelength of 450 nm using a Victor-2 plate reader (PerkinElmer, Waltham, Massachusetts). Each CCK-8 assay was performed in triplicate, and data are presented as means Ϯ SD from 3 replicates. Cell viability was calculated as a percentage of the control, and the IC 50 values of free DOX, L-DOX, F-L-DOX, and F-L-DOX plus 1mM free folate were calculated from growth inhibition curves fitted to the data using OriginPro 7.5 software (OriginLabs, Northampton, Massachusetts).
Detection of cell death by ELISA and TUNEL staining
The cell death detection ELISA plus kit (Roche) was used to measure DNA fragmentation as a marker for apoptosis according to the manufacturer's instructions (21) . Primary cells from 20 cases of NFPA, 1 case of ACTH, 2 cases of GH, and 2 cases of PRL were seeded in 96-well plates at 5 ϫ 10 3 cells/well. After treatment with the indicated doses of free DOX, L-DOX, or F-L-DOX with or without 1mM free folate for 2 hours, cells were washed twice and cultured for an additional 48 hours in folate-free RPMI 1640 supplemented with 10% FBS, B-27 Supplement, and N-2 Supplement in 5% CO 2 at 37°C. Cytoplasmic fractions of control and treated cells were transferred onto streptavidin-coated 96-well plates and incubated with biotinylated mouse antihistone antibody and peroxidase-conjugated mouse anti-DNA antibody at room temperature for 2 hours. Absorbance was determined at 405-490 nm using a Spectra Max Gemini microplate reader. The data shown are means Ϯ SD from 3 replicates.
Apoptotic cells were also detected using the fluorometric TUNEL staining kit (Promega Corp, Madison, Wisconsin). FR␣-positive NFPA cells were cultured on glass-bottomed dishes (Nest Biotechnology Corp) coated with 10-L BD Matrigel Basement Membrane Matrix at a density of 5 ϫ 103 cells/well. The cells were treated with control solvent (PBS), 10M L-DOX, 10M F-L-DOX, or 10M free DOX, in the presence or absence of 1mM folate acid. Treatment was terminated at 2 hours, and the cells were washed twice and cultured in folate-free RPMI 1640 supplemented with 10% FBS, B-27 Supplement, and N-2 Supplement for an additional 48 hours. The cells were fixed in 4% methanol-free formaldehyde in PBS for 25 minutes, washed twice in PBS, and permeabilized with 0.2% Triton X-100 for 5 minutes. After 2 more washes in PBS, cells were equilibrated with equilibration buffer at room temperature for 5 minutes and then incubated with 50-L terminal deoxynucleotidyl transferase fluorescein-12-dUTP for 1 hour at 37°C in a humidified chamber. The reaction was terminated by addition of 2ϫ salt-sodium citrate for 15 minutes at room temperature, and the slides were washed 3 times in PBS and mounted with antifading mounting medium (Golden Bridge International, Inc, Mukilteo, Washington). The cells were observed and photographed under a confocal microscope (Zeiss).
Caspase-3/7, caspase-8, and caspase-9 activity assays
Primary cells from 20 cases of NFPA, 1 case of ACTH cells, 2 cases of GH, and 2 cases of PRL cells were seeded in 96-well white-walled plates and incubated overnight. The medium was replaced with fresh culture medium containing control solvent (PBS) or the indicated doses of L-DOX, F-L-DOX, or free DOX, in the presence or absence of 1mM folic acid. After incubation for 48 hours, Caspase-Glo 3/7, Caspase-Glo 8, and Caspase-Glo 9
Reagents (Promega) were added, and cells were incubated for an additional 90 minutes. Cells were then incubated for 90 minutes in a luciferase substrate mix, and luminescence was measured in a Veritas Microplate Luminometer (Turner BioSystems, Sunnyvale, California). Data shown are means Ϯ SD from 3 replicates.
Western blotting
Expression of cleaved caspase-3, cleaved caspase-8, cleaved caspase-9, Bax, Bcl-2, and PARP (intact and cleaved fragments) in FR␣-positive NFPA cells was analyzed by Western blotting after treatment with control solvent (PBS), 10M free DOX, 10M L-DOX, or 10M F-L-DOX in the presence or absence of 1mM folic acid for 48 hours. Briefly, cell lysates were separated on a 10% polyacrylamide gel, electrophoretically transferred onto a polyvinylidene fluoride membrane (PALL Corp, East Hills, New York), and probed using standard techniques with primary antibodies against cleaved caspase-3, cleaved caspase-8, cleaved caspase-9, Bax, Bcl-2, and PARP. All antibodies were used at a 1:1000 dilution. The secondary antibodies were as follows: horseradish peroxidase-conjugated goat antirabbit IgG (Cell Signaling Technology), horseradish peroxidase-conjugated goat antimouse IgG (Millipore, Bedford, Massachusetts), and horse antihuman IgG (Cell Signaling Technology) for the human anti-␤-actin primary antibody (Santa Cruz Biotechnology, Inc). 
Cell invasion assay
Matrix metalloproteinase (MMP)-2 and MMP-9 ELISA
Human MMP-2 and MMP-9 ELISAs were performed according to the manufacturer's instructions (catalog numbers DMP2F0 and DMP900; R&D Systems, Minneapolis, Minnesota). Briefly, primary cells from 20 cases of NFPA, 1 case of ACTH, 2 cases of GH, and 2 cases of PRL were seeded in 12-well plates at a density of 5 ϫ 10 6 cells/well. The culture medium was replaced with fresh medium containing control solvent (PBS) or the indicated doses of L-DOX, free DOX, or F-L-DOX, in the presence or absence of 1mM folic acid, for 2 hours. After incubation for 72 hours, the supernatants were collected, and cell numbers in each well were counted. The amount of MMP-2 and MMP-9 in 100 L of supernatant was determined and normalized to the remaining cell number. ODs were read at 405 nm, and the level of MMP-2 and MMP-9 expression was calculated as previously described (22) .
Statistical analysis
The data were expressed as means Ϯ SD, with P Ͻ .05 considered statistically significant. The differences among groups were tested by 1-way ANOVA, followed by Dunnett's multiple range test. The differences between 2 groups were evaluated by the unpaired Student's t test. All statistical analyses were performed using JMP 7.0 software (SAS Institute, Cary, North Carolina).
Results
Expression and localization of FR␣ in PA cells
Previous studies demonstrated that FR␣ expressed in the membrane of ovarian cancer cells could be used as a target for antitumor agents (19) . Before exploring whether F-L-DOX exhibited cytotoxic activity against NFPA cells, we analyzed the expression and localization of FR␣ in 43 cases of PA using confocal immunofluorescence. As shown in Figure 1 , HeLa cells included as a positive control showed strong membrane staining with antibody to FR␣ ( Figure 1A ) but no staining when the primary FR␣ antibody was replaced with normal IgG (Figure 1B ), indicating no nonspecific staining from the secondary antibody. The expression of FR␣ in a panel of 43 primary PAs, including 34 NFPAs and 9 FPAs, was analyzed by confocal immunofluorescence. Representative confocal images of the different PAs are shown in Figure 1 , C-G. Of the 34 NFPA cases, 24 showed significant staining of FR␣ in the cell membrane, consistent with our previous study. In contrast, there was no staining on the membrane of FPA cells.
Uptake of FR␣-targeted liposomes by PA cells
The uptake of F-L-calcein and L-calcein by PA cells was analyzed by fluorescence microscopy. F-L-calcein was taken up by FR␣-expressing NFPA cells more efficiently than L-calcein and free calcein (Figure 2A , I-III, respectively). In contrast, NFPA, ACTH, GH, and PRL cells that do not express FR␣ did not take up the F-L-calcein ( Figure  2A , IV and VI-VIII, respectively). Moreover, F-L-calcein uptake was blocked by 1mM free folic acid (Figure 2A, V) . In the 14 cases of NFPA that overexpressed FR␣, cells from 12 cases took up F-L-calcein efficiently but did not take up L-calcein or free calcein. Cells from the 6 cases of NFPA without FR␣ expression did not internalize any F-L-calcein. Measurement of fluorescence intensity by fluorometry showed that the cellular uptake of F-L-calcein was approximately 5 times greater than that of L-calcein and could be blocked by free folate ( Figure 2B ). Taken together, these data showed that FR␣-targeted liposomes could effectively target NFPA cells through FR␣ and that the endocytosis was blocked by free folic acid.
F-L-DOX exhibits cytotoxicity in NFPA cells through the induction of apoptosis
F-L-DOX was previously shown to be much more cytotoxic than L-DOX against the KB cell line (15) . To evaluate the inhibitory effect of F-L-DOX on PA cells, we initially compared the effect of F-L-DOX, L-DOX, and free DOX (as a positive control) on NFPA cells that overexpress FR␣ using the CCK-8 assay. Treatment of FR␣-expressing NFPA cells with free DOX (1M, 5M, 10M, or 20M), L-DOX (1M, 5M, 10M, or 20M), or F-L-DOX (1M, 5M, 10M, or 20M) inhibited cell proliferation in a dose-dependent manner (Figure 3A) . The IC 50 value of L-DOX was approximately 40M; this was 8-fold higher than that of F-L-DOX, suggesting that F-L-DOX is a more effective treatment. Both liposomal formulations had much higher IC 50 values than free DOX, which can be directly taken up by cells. To further demonstrate the targeting ability of F-L-DOX to FR␣ on the surface of NFPA cells, we tested the effect of adding folic acid, which effectively competes for binding to FR␣. As shown in Figure 3A , 1mM folic acid significantly suppressed the antiproliferative effect of F-L-DOX, but did not have any effect on the IC 50 value of L-DOX. Next, we measured the effect of F-L-DOX and L-DOX on NFPA cells that do not express FR␣ and FPA cells, which also lack membrane expression of FR␣. As shown in Figure 3 , B and C, the tumor inhibitory effect of F-L-DOX in these cells was comparable with that of L-DOX, suggesting that expression of FR␣ is critical for the antitumor effect of F-L-DOX against PA.
To investigate whether the cytotoxicity of F-L-DOX involved induction of apoptosis, we treated 14 NFPA cell lines that overexpress FR␣ with F-L-DOX for 48 hours and measured caspase-3/7 activation by caspase-3/7 activity assays. F-L-DOX increased the activation of caspase-3/7 in a dose-dependent manner ( Figure 4A) . Moreover, the activation of caspase-3/7 by F-L-DOX was significantly greater than that induced by L-DOX at concentrations of 1M (P Ͻ .05), 5M (P Ͻ .01), 10M (P Ͻ .001), and 20M (P Ͻ .001). These data indicate that FR␣ mediates the proapoptotic activity of F-L-DOX. Importantly, the increase in caspase-3/7 activity was reflected by the apoptotic fraction of cells: F-L-DOX promoted apoptosis significantly more effectively than L-DOX at concentrations of 1M (P Ͻ .05), 5M (P Ͻ .01), 10M (P Ͻ .01), and 20M (P Ͻ .001) ( Figure 4B ). Treatment with folic acid decreased both the F-L-DOX-mediated caspase-3/7 activity and apoptotic index in NFPA cells. Together, these data indicate that the cytotoxicity of F-L-DOX is dependent on its direct binding to FR␣ and involves subsequent induction of apoptosis.
We also evaluated the effect of F-L-DOX on the activity of caspase-9, a biomarker of the intrinsic apoptosis pathway. As shown in Figure 4C , F-L-DOX promoted the activation of caspase-9 more effectively than L-DOX at concentrations of 1M (P Ͻ .05), 5M (P Ͻ .001), 10M (P Ͻ .001), and 20M (P Ͻ .001). In addition, F-L-DOX also promoted the activation of caspase-8, a biomarker of the extrinsic apoptosis pathway, more effectively than L-DOX at 1M (P Ͻ .05), 5M (P Ͻ .01), 10M (P Ͻ .001), and 20M (P Ͻ .001) ( Figure 4D ). The activation of both caspase-8 and caspase-9 by F-L-DOX was significantly reversed by the addition of 1mM folic acid.
The Western blotting results in Figure 4E also agreed with the results showed in Figure 4 , A, C, and D, which proved the F-L-DOX function on the activity of caspase-3, caspase-8, and caspase-9.
The induction of apoptosis by F-L-DOX was confirmed by visualization of apoptotic cells using TUNEL staining ( Figure 4F ). At a concentration of 10M, F-L-DOX induced apoptosis in FR␣-positive NFPA cells more efficiently than L-DOX. Moreover, 1mM folic acid significantly reduced the proapoptotic effect of F-L-DOX.
In contrast, the proapoptotic effects of F-L-DOX and L-DOX were not significantly different in cells from the 6 cases of NFPA and 5 cases of FPA that were FR␣-negative (data not shown). 
The effect of F-L-DOX on the regulation of apoptotic-related proteins
To further explore the molecular mechanism of F-L-DOX-mediated apoptosis, we performed Western blot analysis to measure the expression of Bcl-2, an inner mitochondrial membrane protein that blocks apoptosis (23); Bax, a Bcl-2-associated protein that promotes apoptosis by competing with Bcl-2 (24); and PARP (25), a nuclear polymerase involved in DNA repair in response to environmental stress. As shown in Figure 5A , 10M F-L-DOX down-regulated the expression of Bcl-2 and up-regulated the expression of Bax more effectively than the same concentration of L-DOX. Densitometric analysis revealed a significantly greater increase in the ratio of Bax to the control and greater decrease in the ratio of Bcl-2 to the control after F-L-DOX treatment compared with L-DOX (P Ͻ .01) ( Figure 5B ). F-L-DOX also induced proteolysis of PARP more effectively than L-DOX ( Figure 5A ), consistent with the data for Bax or Bcl-2 expression ratio, caspase activation, and apoptotic cell death. Moreover, 1mM folic acid significantly suppressed these responses to F-L-DOX. Taken together, these results show that F-L-DOX induces apoptosis in FR␣-expressing NFPA cells and support our hypothesis that FR␣ expression on PA cells is critical for the antitumor activity of F-L-DOX.
Antiinvasive activity of F-L-DOX in NFPA cells
F-L-DOX significantly decreased the invasion of FR␣-expressing NFPA cells through a reconstituted basement membrane (Matrigel) in a concentration-dependent manner ( Figure 6A ). To investigate whether FR␣ is involved in the F-L-DOX-mediated reduction of NFPA cell invasive- plus assay and the Caspase-Glo 3/7 assay, Caspase-Glo 9 and Caspase-Glo 8 assays, and Western blotting were used to detect caspase-3/7 activity (A), apoptosis (B), caspase-9 activity (C), and caspase-8 activity (D) and cleaved caspase-3, caspase-8, and caspase-9 expression (E). The bars show means Ϯ SD from at least 3 independent experiments. n.s, no significant difference; *P Ͻ .05; **P Ͻ .01; ***P Ͻ .001. (F) Typical TUNEL staining images of nuclei of NFPA cells treated with PBS or 10M L-DOX, DOX, or F-L-DOX for 2 hours in the presence or absence of 1mM folic acid (FA). TUNEL staining was performed using the fluorometric TUNEL staining kit.
ness, we compared the antiinvasive effect of F-L-DOX and L-DOX in 14 NFPA cell lines and found that F-L-DOX had a significantly greater antiinvasive effect on NFPA cells than L-DOX at 5M (P Ͻ .05), 10M (P Ͻ .01), and 20M (P Ͻ .001) ( Figure 6A ). Furthermore, F-L-DOXinduced inhibition of tumor cell invasion was completely abrogated by 4-hour incubation with 1mM folic acid, a concentration that effectively blocked the cytotoxicity of F-L-DOX. In the 6 cases of NFPA and 5 case of FA that were FR␣-negative, the antiinvasive effect of F-L-DOX was not significantly different from that of L-DOX.
Effect of F-L-DOX on the regulation of MMP-2 and MMP-9
To investigate a causal link between the modulation of invasiveness and F-L-DOX-induced release of proteolytic enzymes into the cell culture microenvironment, supernatants of NFPA cells that overexpress FR␣ were analyzed for changes in the expression of metallopeptidases after F-L-DOX stimulation ( Figure 6 , B and C). Treatment of NFPA cells with F-L-DOX for 48 hours inhibited MMP-2 protein expression more effectively than treatment with L-DOX at 5M (P Ͻ .05), 10M (P Ͻ .001), and 20M (P Ͻ .001). Simultaneously, concentrations of MMP-9 were also decreased by F-L-DOX treatment to a greater extent than by L-DOX treatment at 1M (P Ͻ .05), 5M (P Ͻ .01), 10M (P Ͻ .01), and 20M (P Ͻ .01). Preincubation of cells with 1mM folic acid showed that the decreases in MMP-2 and MMP-9 levels in response to F-L-DOX treatment were antagonized by 1mM folic acid, indicating that they were mediated by FR␣. In FR␣-negative NFPA and FA cells, the effects of F-L-DOX on MMP-2 and MMP-9 were not significantly different from those of L-DOX.
Discussion
Data presented in this study provide considerable evidence supporting FR␣ as a target for the development of novel antitumor therapeutics for the treatment of NFPA. Our previous study found that F-L-DOX, a new FR␣-targeted agent, showed excellent targeting ability and antitumor effects in KB cancer cells. Previous studies have demonstrated that FR␣ is uniquely overexpressed in NFPAs but not in FPAs or normal pituitary glands (16, 17) , and our latest study showed that expression of FR␣ was positively correlated with tumor invasiveness and proliferation in NFPAs (18) . These findings suggested that FR␣-targeted agents might be useful for the treatment of NFPAs, especially invasive NFPAs that are refractory to conventional therapies. In the present study, we showed that F-L-DOX does exert an antitumor effect against NFPA cells. FR␣-targeted liposomal-calcein was taken up by FR␣-positive NFPA cells more effectively than L-calcein due to overexpression of FR␣ on the cell membrane. In contrast, FPAs lacking FR␣ expression could not internalize the FR␣- Our findings are consistent with previous reports showing that a FR␣-targeted antitumor agent significantly and dose dependently reduced the cell viability of FR␣-overexpressing tumors, such as ovarian cancer in vitro and in vivo (26 -28) . Here, we showed that F-L-DOX induced the activation of caspases, down-regulated the expression of Bcl-2, and up-regulated the expression of Bax in NFPAs. Members of the Bcl-2 family of proteins are critical regulators of the apoptotic pathway (29) . In particular, the ratio of Bax to Bcl-2 is a decisive factor in determining whether cells will undergo apoptosis under experimental conditions that promote cell death (30) . We observed a decrease in Bcl-2 protein expression and an increase in Bax expression in NFPA cells after treatment with F-L-DOX that shifted the ratio of Bax to Bcl-2 in favor of apoptosis. The up-regulation of Bax and down-modulation of Bcl-2 were accompanied by activation of caspase-9 and the executioner caspase-3/7. Expression of caspase-8, the initiator caspase of the death receptor apoptotic pathway, was also regulated by F-L-DOX. Moreover, F-L-DOX-treated NFPA cells showed increased PARP proteolysis, which is a hallmark of apoptosis (31) . These data indicate that death receptor and mitochondrial apoptotic pathways participate in F-L-DOX-induced NFPA cell apoptosis.
Inhibition of cell invasion is of great importance in the prevention of tumor recurrence and is another critical index in antitumor agent development (32) . Our study showed that F-L-DOX decreased NFPA cell invasion in a concentration-dependent manner. Few reports have considered the antiinvasive effects of folate-linked agents and explored the molecular mechanisms of this type of agents. Previous studies showing that blueberry phytochemicals and cannabinoids mediate tumor invasiveness through regulation of MMPs (33) provided the platform for the molecular research in our study. Our results showed that F-L-DOX down-regulated the expression of MMP-2 and MMP-9 in NFPA cells more effectively than L-DOX. Consistent with the hypothesis that the MMP system mediates the antiinvasion effect of F-L-DOX, MMP activity was persistently inhibited after 72 hours of F-L-DOX treatment. In contrast, at the same time point, L-DOX did not significantly inhibit expression of MMP-2 and MMP-9. Furthermore, folic acid suppressed the cytotoxic effect of F-L-DOX, caused a profound reduction in the inhibition of MMP expression by F-L-DOX, and reversed the F-L-DOX-mediated effect on invasion. These results suggest that MMPs play a critical role in mediating the antiinvasive effect of F-L-DOX on NFPA cells. Thus, our findings suggest that the reduction in invasiveness observed when The bars show means Ϯ SD from at least 3 independent experiments. n.s., no significant difference; *P Ͻ .05, **P Ͻ .01, ***P Ͻ .001. RLU, relative light unit; cont, control.
cells were treated with F-L-DOX is mechanistically related to the modulation of matrix-degrading enzymes.
In conclusion, we present evidence supporting the use of F-L-DOX in the treatment of FR␣-positive NFPAs. Furthermore, our study also provides novel insights into the mechanism of action of folate-linked antitumor agents in tumor treatment. Future in vivo studies are needed to determine the targeting ability and effect of F-L-DOX in NFPAs.
